All Stories

  1. Regression to the mean: a primer for evidence-based medicine practitioners
  2. BIAS, BENEFIT, OR BOTH? SURVEYING PERCEPTIONS OF AI IN HEALTHCARE
  3. Benchmarking DNA foundation models for genomic and genetic tasks
  4. An alternative method for assessing the fragility of survival analysis results: a proof-of-concept study based on the log-rank test
  5. Leveraging AI for Meta‐Analysis: Evaluating LLMs in Detecting Publication Bias for Next‐Generation Evidence Synthesis
  6. Retiring the Term “Weighted Mean Difference” in Contemporary Evidence Synthesis
  7. Lifecycles of Cochrane Systematic Reviews (2003–2024): A Bibliographic Study
  8. Prospective registration was associated with a reduced risk of bias for randomized controlled trials: a meta-research study
  9. Post‐cesarean skin closure with metal staples versus subcuticular suture in obese patients: A systematic review and meta‐analysis of randomized controlled trials
  10. Tipping point analysis in network meta-analysis
  11. Prediction Performance of Earlier Studies for Later Studies in Cochrane Reviews
  12. Lack of reproducibility of trial sequential analyses: a meta-epidemiological study
  13. Confidence intervals of the relative risk and odds ratio can predict when the optimal information size in a meta-analysis is not met
  14. Trial sequential analysis involving same-year studies requires careful temporal ordering
  15. The Role of Double‐Zero‐Event Studies in Evidence Synthesis: Evaluating Robustness Using the Fragility Index
  16. Assessment of inverse publication bias in safety outcomes: an empirical analysis
  17. Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index
  18. Towards the automatic risk of bias assessment on randomized controlled trials: A comparison of RobotReviewer and humans
  19. Meta-analysis of continuous outcomes: a user’s guide for analysis and interpretation
  20. A brief note on the common (fixed)-effect meta-analysis model: comment on Veroniki and McKenzie
  21. Comparisons of various estimates of the I2 statistic for quantifying between-study heterogeneity in meta-analysis
  22. Comparisons of the mean differences and standardized mean differences for continuous outcome measures on the same scale
  23. Structural Equation Modeling Using R/SAS: A Step-by-Step Approach with Real Data Analysis
  24. Sensitivity analysis with iterative outlier detection for systematic reviews and meta‐analyses
  25. Choice of link functions for generalized linear mixed models in meta-analyses of proportions
  26. The impact of studies with no events in both arms on meta-analysis of rare events: A simulation study using generalized linear mixed model
  27. Bayesian hierarchical models incorporating study‐level covariates for multivariate meta‐analysis of diagnostic tests without a gold standard with application to COVID‐19
  28. The Active Ingredient in Reading Comprehension Strategy Intervention for Struggling Readers: A Bayesian Network Meta-analysis
  29. Methods for deriving risk difference (absolute risk reduction) from a meta-analysis
  30. The normality assumption on between-study random effects was questionable in a considerable number of Cochrane meta-analyses
  31. Assessing the robustness of results from clinical trials and meta-analyses with the fragility index
  32. THE EFFECT DIRECTION SHOULD BE TAKEN INTO ACCOUNT WHEN ASSESSING SMALL-STUDY EFFECTS
  33. Meta-analysis methods for risk difference: A comparison of different models
  34. Data extraction error in pharmaceutical versus non-pharmaceutical interventions for evidence synthesis: Study protocol for a crossover trial
  35. Limits in the search date for rapid reviews of diagnostic test accuracy studies
  36. A Retrospective Analysis of Biological Complications of Dental Implants
  37. A Bayesian model for combining standardized mean differences and odds ratios in the same meta-analysis
  38. Synthesizing evidence from the earliest studies to support decision‐making: To what extent could the evidence be reliable?
  39. Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package
  40. Accounting for publication bias using a bivariate trim and fill meta‐analysis procedure
  41. Meta-analysis methods for risk difference: a comparison of different models
  42. Empirical comparisons of meta-analysis methods for diagnostic studies: a meta-epidemiological study
  43. Comment on a review of methods to assess publication and other reporting biases in meta‐analysis
  44. Empirical comparisons of heterogeneity magnitudes of the risk difference, relative risk, and odds ratio
  45. The Odds Ratio is “portable” across baseline risk but not the Relative Risk: Time to do away with the log link in binomial regression
  46. Bridging randomized controlled trials and single-arm trials using commensurate priors in arm-based network meta-analysis
  47. A penalization approach to random‐effects meta‐analysis
  48. Methodological quality for systematic reviews of adverse events with surgical interventions: a cross-sectional survey
  49. Predictive P-score for treatment ranking in Bayesian network meta-analysis
  50. Estimating Partial Standardized Mean Differences from Regression Models
  51. Rapid evidence synthesis approach for limits on the search date: How rapid could it be?
  52. Empirical Comparisons of 12 Meta-analysis Methods for Synthesizing Proportions of Binary Outcomes
  53. The impact of studies with no events in both arms on meta-analysis of rare events: a simulation study using generalized linear mixed model
  54. Synthesis of evidence from zero‐events studies: A comparison of one‐stage framework methods
  55. Good Statistical Practices for Contemporary Meta-Analysis: Examples Based on a Systematic Review on COVID-19 in Pregnancy
  56. Bayesian meta‐analysis using SAS PROC BGLIMM
  57. A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies
  58. Utilization of the evidence from studies with no events in meta-analyses of adverse events: an empirical investigation
  59. Methodological assessment of systematic reviews and meta‐analyses on COVID ‐19: A meta‐epidemiological study
  60. Double-zero-event studies matter: A re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  61. Bayesian Methods for Meta-Analyses of Binary Outcomes: Implementations, Examples, and Impact of Priors
  62. The influence of insertion torque values on the failure and complication rates of dental implants: A systematic review and meta‐analysis
  63. Many meta-analyses of rare events in the Cochrane Database of Systematic Reviews were underpowered
  64. Empirical assessment of prediction intervals in Cochrane meta‐analyses
  65. Prior Choices of Between-Study Heterogeneity in Contemporary Bayesian Network Meta-analyses: an Empirical Study
  66. Systematic identification of risk factors and drug repurposing options for Alzheimer's disease
  67. BayesSenMC: an R package for Bayesian Sensitivity Analysis of Misclassification
  68. Evidence inconsistency degrees of freedom in Bayesian network meta-analysis
  69. Protocols for meta-analysis of intervention safety seldom specified methods to deal with rare events
  70. PALM: Patient-centered Treatment Ranking via Large-scale Multivariate Network Meta-analysis
  71. Evaluation of various estimators for standardized mean difference in meta‐analysis
  72. Questionable utility of the relative risk in clinical research: a call for change to practice
  73. A Bayesian Approach for Determining the Relationship Between Various Elongate Mineral Particles (EMPs) Definitions
  74. Fragility index of network meta-analysis with application to smoking cessation data
  75. Peto odds ratios demonstrate no advantage over classic odds ratios in meta-analysis of binary rare outcomes
  76. Meta-analysis of Proportions Using Generalized Linear Mixed Models
  77. Double-zero-event studies matter: a re-evaluation of physical distancing, face masks, and eye protection for preventing person-to-person transmission of COVID-19 and its policy impact
  78. A variance shrinkage method improves arm-based Bayesian network meta-analysis
  79. Accounting for small-study effects using a bivariate trim and fill meta-analysis procedure
  80. Arcsine‐based transformations for meta‐analysis of proportions: Pros, cons, and alternatives
  81. Systematic identification of modifiable risk factors and drug repurposing options for Alzheimer’s disease: Mendelian randomization analyses
  82. Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions
  83. Effects of treatment classifications in network meta-analysis
  84. A Bayesian approach to assessing small‐study effects in meta‐analysis of a binary outcome with controlled false positive rate
  85. Laplace approximation, penalized quasi-likelihood, and adaptive Gauss–Hermite quadrature for generalized linear mixed models: towards meta-analysis of binary outcome with sparse data
  86. Factors that impact fragility index and their visualizations
  87. The impact of covariance priors on arm‐based Bayesian network meta‐analyses with binary outcomes
  88. Hybrid test for publication bias in meta-analysis
  89. P value–driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses
  90. On evidence cycles in network meta-analysis
  91. Use of Prediction Intervals in Network Meta-analysis
  92. The magnitude of small-study effects in the Cochrane Database of Systematic Reviews: an empirical study of nearly 30 000 meta-analyses
  93. Comparison of four heterogeneity measures for meta‐analysis
  94. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses
  95. Real-world Performance of Meta-analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews
  96. Graphical augmentations to sample-size-based funnel plot in meta-analysis
  97. Borrowing of strength from indirect evidence in 40 network meta-analyses
  98. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation
  99. Performance of Between-study Heterogeneity Measures in the Cochrane Library
  100. Re: Incidence and Risk Factors for Prediabetes and Diabetes Mellitus Among HIV-infected Adults on Antiretroviral Therapy: A Systematic Review and Meta-analysis
  101. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model
  102. Bias caused by sampling error in meta-analysis with small sample sizes
  103. Quantifying and presenting overall evidence in network meta-analysis
  104. Empirical Comparison of Publication Bias Tests in Meta-Analysis
  105. The effect of publication bias magnitude and direction on the certainty in evidence
  106. Bayesian multivariate meta-analysis of multiple factors
  107. Quantifying publication bias in meta-analysis
  108. Rejoinder to “quantifying publication bias in meta-analysis”
  109. Cross channel effects of search engine advertising on brick & mortar retail sales: Meta analysis of large scale field experiments on Google.com
  110. Performing Arm-Based Network Meta-Analysis in R with the pcnetmeta Package
  111. An adaptive two-sample test for high-dimensional means
  112. Sensitivity to Excluding Treatments in Network Meta-analysis
  113. Alternative measures of between-study heterogeneity in meta-analysis: Reducing the impact of outlying studies